{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:05:05Z","timestamp":1777525505199,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejca.2018.02.022","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T07:25:02Z","timestamp":1523604302000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Risk stratification of sentinel node\u2013positive melanoma patients defines surgical management and adjuvant therapy treatment considerations"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0034-3575","authenticated-orcid":false,"given":"Dani\u00eblle","family":"Verver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"van Klaveren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry W.E.M.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Testori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara L.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.02.022_bib1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.ejca.2018.02.022_bib3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2018.02.022_bib4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2018.02.022_bib5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.02.022_bib6","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.02.022_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib8","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib9","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib10","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.02.022_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2018.02.022_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2018.02.022_bib13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/annonc\/mdl176","article-title":"Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?","volume":"17","author":"van Akkooi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib14","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.2004.12.177","article-title":"The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement","volume":"22","author":"Dewar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib15","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2010.31.6760","article-title":"Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria","volume":"29","author":"van der Ploeg","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/bjs.10475","article-title":"Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma","volume":"104","author":"Oude Ophuis","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2018.02.022_bib17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ejso.2016.05.012","article-title":"The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - an EORTC Melanoma Group study","volume":"42","author":"Oude Ophuis","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2018.02.022_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archsurg.134.1.43","article-title":"Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins","volume":"134","author":"Bostick","year":"1999","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejca.2018.02.022_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/path.1365","article-title":"The development of optimal pathological assessment of sentinel lymph nodes for melanoma","volume":"200","author":"Cook","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2018.02.022_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2018.02.022_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bjc.6601117","article-title":"Survival analysis part IV: further concepts and methods in survival analysis","volume":"89","author":"Clark","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.02.022_bib22","first-page":"1","article-title":"MICE: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ejca.2018.02.022_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2017.11.023","article-title":"Eighth American Joint Committee on Cancer (AJCC) melanoma classification: let us reconsider stage III","volume":"91","author":"Grob","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.02.022_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejca.2017.09.014","article-title":"The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients","volume":"86","author":"Eggermont","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.02.022_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.12.002","article-title":"The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival","volume":"91","author":"Ulmer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.02.022_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jamcollsurg.2014.02.019","article-title":"Addition of an iliac\/obturator lymph node dissection does not improve nodal recurrence or survival in melanoma","volume":"219","author":"Egger","year":"2014","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejca.2018.02.022_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejca.2011.09.028","article-title":"Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991","volume":"48","author":"Eggermont","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.02.022_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2015.11.014","article-title":"Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity","volume":"55","author":"Eggermont","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.02.022_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918302296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918302296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T08:06:42Z","timestamp":1550477202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918302296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":29,"alternative-id":["S0959804918302296"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.02.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification of sentinel node\u2013positive melanoma patients defines surgical management and adjuvant therapy treatment considerations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}